Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
339
datasets available to search
ShareScore release 0.9.0
Dataset results
339 results for “CML”
Data for a CML blackout gap detection example
<p><em>blackout_example_cmls.nc</em> consists of three years of data from two commercial microwave links. It includes transmitted and recieved signal levels with a temporal resolution of one minute.</p> <p><em>blackout_example_radar_reference.nc</em> consists of three years of rainfall data from RADKLIM-YW, a radar product from the German Weather Service, path-averaged along the two example CMLs.</p>
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
ClinicalTrials.gov study NCT03578367. IPD Sharing: YES. Countries: 15. Publications: 1.
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
ClinicalTrials.gov study NCT02467270. IPD Sharing: YES. Countries: 21. Publications: 2.
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov study NCT01667133. IPD Sharing: YES. Countries: 1. Publications: 2.
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
ClinicalTrials.gov study NCT01274351. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
ClinicalTrials.gov study NCT04971226. IPD Sharing: YES. Countries: 29. Publications: 2.
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
ClinicalTrials.gov study NCT01844765. IPD Sharing: YES. Countries: 13. Publications: 3.
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
ClinicalTrials.gov study NCT03106779. IPD Sharing: YES. Countries: 25. Publications: 5.
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov study NCT01207440. IPD Sharing: YES. Countries: 11. Publications: 5.
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
ClinicalTrials.gov study NCT01743989. IPD Sharing: YES. Countries: 21. Publications: 1.
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
ClinicalTrials.gov study NCT00471497. IPD Sharing: YES. Countries: 35. Publications: 8.
Showcase video of hourly RADOLAN and CML rainfall maps
<p>Supplementary material to Graf et al. (2020): Video of a 48 hour showcase of RADOLAN-RW and CML derived rainfall maps from 12.05.2018 - 14.05.2018 with an hourly resolution. RADOLAN-RW is a rainfall product made available by the German Weather Service and CML data is derived with an automated data acquisition from Ericsson, Germany (Chwala et al. 2016). </p> <p>Graf, M., Chwala, C., Polz, J., and Kunstmann, H.: Rainfall estimation from a German-wide commercial microwave link network: optimized processing and validation for 1 year of data, Hydrol. Earth Syst. Sci., 24, 2931–2950, https://doi.org/10.5194/hess-24-2931-2020, 2020.</p> <p>Chwala, C., Keis, F., and Kunstmann, H.: Real-time data acquisition of commercial microwave link networks for hydrometeorological applications, Atmos. Meas. Tech., 9, 991–999, https://doi.org/10.5194/amt-9-991-2016, 2016.</p>
Data Set available for Liquid Biopsy of CML Diagnosis
<p><em><span>Chronic Myeloid Leukemia, CML, is caused in patients with myeloproliferative disorders by the presence of BCR::ABL1. The research discussed the integration of microfluidic chips with biosensors for the purpose of detecting biomarkers in peripheral blood thereby showing the raw experimental data set avaialble, liquid bipsy sample set available and Calculation for methods and data Simulation along with graphs, which could obviate the need for painful biopsies, thereby improving diagnostic accuracy and accessibility.</span></em></p>
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
ClinicalTrials.gov study NCT00375219. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
ClinicalTrials.gov study NCT00109707. IPD Sharing: Not stated. Countries: 22. Publications: 6.
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
ClinicalTrials.gov study NCT01650805. IPD Sharing: Not stated. Countries: 24. Publications: 2.
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
ClinicalTrials.gov study NCT00462943. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
ClinicalTrials.gov study NCT00644878. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
ClinicalTrials.gov study NCT01275196. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Per
ClinicalTrials.gov study NCT00760877. IPD Sharing: Not stated. Countries: 6. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.